Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Summary

The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.

Timeline

Start

2021-01-20

Primary completion

2022-04-27

Completion

2023-06-02

Drugs

Indications